April 23, 2025 – Foothill Ranch, CA – TAE Life Sciences (TLS), a pioneer in next-generation cancer treatment technologies, is pleased to announce a strategic partnership with Transmedic, a leading medical technology distributor in Southeast Asia, to bring Boron Neutron Capture Therapy (BNCT) to the region. This collaboration marks a significant milestone in expanding access to TLS’s cutting-edge Alphabeam™ BNCT system, a novel particle therapy platform designed for treating invasive, recurrent, and difficult-to-treat cancers.
Transmedic will represent TAE Life Sciences in key Southeast Asian markets, providing clinical, operational, and regulatory support to bring Alphabeam BNCT to regional hospitals and cancer centers. The partnership will focus initially on countries such as Singapore, Malaysia, Hong Kong, and Thailand, where demand for advanced oncology treatment options continues to grow.
“We’re thrilled to partner with Transmedic, whose established presence and deep expertise in the region make them an ideal collaborator for expanding BNCT in Southeast Asia,” said Rob Hill, CEO of TAE Life Sciences. “Our Alphabeam system is uniquely designed for hospital-based environments and offers new hope for patients with aggressive tumors that are resistant to traditional treatments.”
BNCT is a biologically targeted form of radiation therapy that selectively destroys tumor cells while minimizing damage to healthy tissue. The Alphabeam system is the first and only accelerator-based BNCT platform developed specifically for clinical use and optimized for integration within modern healthcare settings.
“Transmedic is excited to work with TAE Life Sciences to introduce BNCT to our region,” said Kristine James, CEO of Transmedic. “This partnership aligns with our mission to bring innovative medical solutions to Southeast Asia and help improve outcomes for patients facing the most challenging cancers.”
This agreement is part of TAE Life Sciences’ broader global expansion strategy, building on recent collaborations in Asia, Europe, and North America to make BNCT more accessible worldwide.
About TAE Life Sciences
TAE Life Sciences is a biotechnology company pioneering the development of accelerator-based BNCT solutions for treating aggressive and treatment-resistant cancers. The company’s Alphabeam BNCT system and novel boron drugs are designed to enable safe and effective BNCT treatment worldwide. More information about TAE Life Sciences is available at taelifesciences.com
About Transmedic
Transmedic connects the world’s leading healthcare solutions to the needs of people across Asia. Headquartered in Singapore, we are a leading independent distributor of innovative medical technologies, specializing in therapeutic areas such as Radiation Oncology, Cardiovascular, Orthopaedics, In-vitro Diagnostics, Ophthalmology, Blood Therapy, Endovascular, and Abdo-Pelvic. With over 40 years of local expertise, we provide healthcare professionals and institutions throughout ASEAN and Hong Kong with globally sourced solutions, trusted networks, and dedicated support to enhance patient care. Transmedic’s regional presence spans Singapore, Malaysia, Thailand, Indonesia, Hong Kong, the Philippines, and Vietnam, empowering healthcare systems for better outcomes. Learn more: transmedicgroup.com
